CLASSYS Inc (214150) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of CLASSYS Inc stock KRW 52,952, price KRW 25,850, upside +104.8%, quality 74 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 13,112 KRW – 75,600 KRW · fair‑value band 29,680 KRW – 89,694 KRW · the 25,850 KRW price screens below the 52,952 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow CLASSYS in your weekly email
Every Wednesday you see whether CLASSYS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CLASSYS Inc. provides medical aesthetics devices worldwide.
Show moreShow less
The company offers ULTRAFORMER MPT, a solution for eyebrow lifting; ULTRAFORMER III, an ultrasound surgical device used for tissue coagulation in eyelid lifting, and for skin tightening and improving subcutaneous tissue elasticity in the face (cheeks), abdomen, and thighs; VOLNEWMER, a monopolar radiofrequency therapeutic equipment used to coagulate skin tissue; Secret RF, a device that delivers radio frequency energy into the skin; Secret PRO, a multiple fractional device that delivers micro-level laser beams fractionally to the tissue; Secret DUO, a multi-functional device that delivers high-frequency energy through needle electrodes; and Fortra, a 4 wavelengths diode laser.
It also provides SCIZER and CLATUU Alpha for non-invasive subcutaneous fat reduction; Ulfit, a medical device used to improve skin elasticity and subcutaneous tissue in the abdomen and thighs; Refit, a medical device that uses RF and negative pressure to increase tissue temperature and blood flow, relieving pain in the treated area; AQUAPURE, a combination of four handpieces used for acne suction, muscle pain relief, and other pain relief; FORSHAPE, an RF treatment system used to increase metabolism, blood circulation, and tissue recovery; and INTRASURE for lifting, wrinkle reduction, body contouring, and cellulite reduction.
In addition, the company offers AQUAPURE II, which exfoliates hyper-keratinized dead skin cells; Reepot, a medical device that delivers energy to tissue; veloce, which enhances treatment results; Pento, a laser surgical device for tissue incision, destruction, and removal; and curas hybrid laser system.
Further, it sells cosmetics. The company offers its products under the Classys, Cluederm, and Skederm brands. It serves distributors, clinics, hospitals, and direct end users. The company was founded in 2007 and is headquartered in Seoul, South Korea.
CLASSYS Inc. is a subsidiary of BCPE Centur Investments, LP.
Stock analysis
CLASSYS Inc (214150) currently trades at 25,850 KRW, while our model-based Fair Value estimate is 52,952 KRW, implying the stock looks roughly 51% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 91,048 KRW per share, and 19 of the 26 models we run sit above the 25,850 KRW price.
Bear case: the Economic Profit group reads lowest at 27,487 KRW, and 7 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 29,680 KRW (bear) to 89,694 KRW (bull), the price of 25,850 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
CLASSYS Inc reported revenue of 337B KRW in FY2025 versus 101B KRW in FY2021, a compound +35.3%/yr. Reported net income was 132B KRW in FY2025, compounding +31.7%/yr from FY2021.
Key figures
Market cap 1.7T KRW (≈ $1.2B) Small · P/E ratio 12.1 · P/S ratio 4.58 · EPS (TTM) 2,110 KRW · Dividend yield 3.9% · Net margin 37.3% · Return on equity 25.6% · Return on assets (EBIT) 22.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 90 out of 100 (low confidence).
What moves the price
The share trades about 66% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 105%, 214150 screens cheaper than that median.
Fair Value models
Bear29,680 KRWFair Value 52,952 KRWBull89,694 KRW
Price 25,850 KRW · Upside +104.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (949.05 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+38.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.5%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.2%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+33.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.1%
Dividend (yield on the price)3.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.27.9% vs 63.6%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.53% → 51%
2025 sits 73% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+22.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −1.3% a year for the price and +20.4% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (10 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: High margins represent the main strength, while thin public data and unclear durability form the central weakness amid limited operational detail.
Main risk: Intensifying domestic competition together with Brazil delays threatens sales estimates and profit margins through lower demand and operational setbacks.
CLASSYS is expanding globally with new commercial and tech leadership plus its first US consumer device launch. Yet recent analyst notes highlight intensifying domestic competition and Brazil delays that caused Q3 profit to miss consensus and prompted lowered 2026 sales estimates below prior guidance. Our models see it as undervalued. Will the international momentum offset these near-term pressures, or will local headwinds slow the overall trajectory?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+104.8% · Top 25%
Profitability
Return on equity (12 months)25.6% · Top 25%
Return on assets18.7% · Top 25%
Net margin (12 months)37.3% · Top 25%
Operating margin (12 months)41.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)26.7% · Top 25%
Dividend yield (12 months)3.9% · Top 25%
Balance sheet
Debt / equity0.11× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CLASSYS Inc Fair Value". https://www.fairvalue-calculator.com/stock/214150
Frequently asked questions
Is CLASSYS Inc (214150) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 52,952 KRW versus a price of 25,850 KRW, about +105% upside (undervalued).
What is the fair value of 214150?
Our model-based fair value for CLASSYS Inc is 52,952 KRW (as of Nov 7, 2026), built from audited fundamentals. The current price: 25,850 KRW.
What is the quality score of 214150?
CLASSYS Inc has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CLASSYS Inc (214150)?
Our model-based price target is the fair value of 52,952 KRW (as of Nov 7, 2026) from 26 valuation models. Cautious scenario 29,680 KRW, optimistic scenario 89,694 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the CLASSYS Inc stock forecast for 2026?
Our models put fair value at 52,952 KRW, about +105% upside versus a price of 25,850 KRW (undervalued). Cautious scenario 29,680 KRW, optimistic scenario 89,694 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CLASSYS Inc (214150)?
CLASSYS Inc reported trailing-twelve-month revenue of about 369B KRW (latest available figure, as of Nov 7, 2026).
Does CLASSYS Inc pay a dividend?
CLASSYS Inc currently shows a dividend yield of 3.87% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of CLASSYS Inc (214150) and when is the ex-dividend date?
CLASSYS Inc pays a dividend of 1,000 KRW per share a year, a dividend yield of 3.9%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2017. The payout ratio is 47.4% of earnings. Free cash flow covers the dividend 2.22 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into CLASSYS Inc (214150)?
For today's price to be fair in a discounted-cash-flow model, CLASSYS Inc would have to grow free cash flow by +0.8 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +34.5 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 214150 use?
Our models discount CLASSYS Inc at 10.5 %: a base by market capitalisation (small), damped by beta 0.62, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CLASSYS Inc that is +0.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has CLASSYS Inc (214150) delivered so far?
Over the past 5 years revenue at CLASSYS Inc grew +34.5 % a year. The price currently implies free-cash-flow growth of +0.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CLASSYS Inc (214150) growing?
The median revenue growth in the sector is +14.1 % a year. That is the yardstick for the growth priced into CLASSYS Inc (+0.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CLASSYS Inc (214150)?
The free-cash-flow yield on the price is 8.57 %: that much free cash flow CLASSYS Inc produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CLASSYS Inc (214150)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CLASSYS Inc it is 52,952 KRW per share (as of Nov 7, 2026), against a price of 25,850 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is CLASSYS Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 214150 trades below its calculated fair value: price 25,850 KRW, fair value 52,952 KRW, a gap of about +105% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 214150?
No. The price is what the market pays today (25,850 KRW); the fair value is what the company's own numbers justify (52,952 KRW). For CLASSYS Inc the two are 27,102 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CLASSYS Inc worth?
The market values CLASSYS Inc at about 1.7T KRW (market capitalisation, as of Nov 7, 2026). Per share that is 25,850 KRW; our models calculate a fair value of 52,952 KRW per share.
What do the bullish and bearish scenarios say about 214150?
Our models span a range for CLASSYS Inc: cautious scenario 29,680 KRW, base 52,952 KRW, optimistic 89,694 KRW per share (as of Nov 7, 2026, price 25,850 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 214150?
CLASSYS Inc trades at a price-to-earnings ratio of 12.1 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 52,952 KRW is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 27.3. Other multiples: P/B 3.1, P/S 4.6, EV/EBITDA 9.3.
How solid is the balance sheet of CLASSYS Inc (214150)?
Balance-sheet figures for CLASSYS Inc (as of Nov 7, 2026): return on equity 25.6%, debt of 0.11 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 214150 from its 52-week high?
CLASSYS Inc trades at 25,850 KRW, about 66% below its 52-week high of 75,600 KRW and at the low of 25,850 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 52,952 KRW is for.
Which stocks are comparable to CLASSYS Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CLASSYS Inc stock attractive at the current price?
The data as of Nov 7, 2026: price 25,850 KRW, calculated fair value 52,952 KRW (+105%), Quality Score 74/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 214150 calculated?
We run CLASSYS Inc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 52,952 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. CLASSYS Inc currently trades 51% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CLASSYS Inc (214150)?
The closing price on Nov 6, 2026 was 25,850 KRW. Our model-based fair value is 52,952 KRW, about +105% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CLASSYS Inc right now?
The price is below even our cautious bear case (29,680 KRW). The market is more pessimistic than our downside scenario. The model range is unusually wide (29,680 KRW to 89,694 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (74/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of CLASSYS Inc
How large is the market capitalisation of CLASSYS Inc (214150)?
The market capitalisation of CLASSYS Inc is 1.7T KRW (≈ $1.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CLASSYS Inc (214150)?
The price-to-sales ratio of CLASSYS Inc is 4.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CLASSYS Inc (214150)?
Earnings per share at CLASSYS Inc are 2,110 KRW (price ÷ EPS = P/E 12.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CLASSYS Inc (214150)?
The dividend yield of CLASSYS Inc is 3.9% (payout 47.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CLASSYS Inc (214150)?
The net margin of CLASSYS Inc is 37.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CLASSYS Inc (214150)?
The return on equity (ROE) of CLASSYS Inc is 25.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CLASSYS Inc (214150)?
On an EBIT basis the return on assets of CLASSYS Inc is 22.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CLASSYS Inc (214150)?
The operating margin of CLASSYS Inc is 41.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CLASSYS Inc (214150)?
Revenue at CLASSYS Inc is growing +26.7% versus a year earlier (3y avg +33.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CLASSYS Inc (214150)?
Earnings per share at CLASSYS Inc are growing +8.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does CLASSYS Inc (214150) carry?
The net debt of CLASSYS Inc is 49.0B KRW (fiscal year 2025, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch CLASSYS Inc in the live analysis
One click puts CLASSYS Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026